AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
about
Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivationCombining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cellsCopine-III interacts with ErbB2 and promotes tumor cell migrationSurvival of cancer cells is maintained by EGFR independent of its kinase activityAntiangiogenesis cocktails - stirred or shaken?Dual Inhibitor AEE788 Reduces Tumor Growth in Preclinical Models of MedulloblastomaPhosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitorsMechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate CancerCurrent Understanding on EGFR and Wnt/β-Catenin Signaling in Glioma and Their Possible CrosstalkThe epidermal growth factor receptor variant III (EGFRvIII): where wild things are alteredStructures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor SensitivityRole of receptor tyrosine kinases in gastric cancer: new targets for a selective therapyLapatinib-binding protein kinases in the African trypanosome: identification of cellular targets for kinase-directed chemical scaffoldsEfficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity.Imaging hemodynamics.Identification of gefitinib off-targets using a structure-based systems biology approach; their validation with reverse docking and retrospective data miningCatalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogueNew chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs'Druggable' alterations detected by Ion Torrent in metastatic colorectal cancer patientsEGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.Involvement of de novo synthesized palmitate and mitochondrial EGFR in EGF induced mitochondrial fusion of cancer cells.Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunitiesNew approaches in angiogenic targeting for colorectal cancer.Development and strategies of VEGFR-2/KDR inhibitors.Apoptotic cells initiate endothelial cell sprouting via electrostatic signaling.Structure, development, preclinical and clinical efficacy of tivozanib (KRN-951, AV-951).Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.Targeting the function of the HER2 oncogene in human cancer therapeutics.Induction of apoptosis in tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice.Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors.Update on clinical radiobiologyRapid and accurate ranking of binding affinities of epidermal growth factor receptor sequences with selected lung cancer drugsTargeting receptor tyrosine kinase on lymphatic endothelial cells for the therapy of colon cancer lymph node metastasis.The merits of vascular targeting for gynecologic malignancies.Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients.Simultaneous inhibition of EGFR/VEGFR and cyclooxygenase-2 targets stemness-related pathways in colorectal cancer cellsTherapeutic targeting of receptor tyrosine kinases in lung cancer.Antitumor efficacy of colon-specific HPMA copolymer/9-aminocamptothecin conjugates in mice bearing human-colon carcinoma xenograftsCombined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck.Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice
P2860
Q21195230-DA8C6420-C288-4A69-839C-2C318304478EQ21260390-B8B81DC3-063A-4E32-B99C-FAAA0161446EQ22001536-49BAAF9E-6917-4212-9750-6F980C1285C1Q24309274-FCC51074-FFC6-42D1-811C-65E8E563982CQ24548357-83101306-3CA4-4B74-8CD0-87C62AA6BCE4Q24615472-AF704D0D-ECE6-4D58-B1E9-6237C867FE55Q24644787-781A006C-138E-4CE2-B1D3-9524198615FBQ26766638-0560C5F4-2007-4AE5-844D-504F164F430DQ26865911-CE602A10-C480-44B0-A604-E04C75496E43Q27015045-0B3CCA5D-8FB8-47B6-9F70-AFFE66A86FC5Q27644014-3A308930-E3B9-4D1B-9D26-5929075E7A0AQ28242840-7C07388C-AA77-4711-BF7E-4C83AFA3662BQ28486270-66A1266B-220C-4D8D-B981-E795C6FBAE83Q30313117-C4983907-7AD7-4429-9F72-89C291D7A73CQ30439974-CA396E15-9DED-4776-832D-CEDBB67F2836Q31132212-177FE9F3-0809-43D5-8475-D28F3EA2870FQ33398170-C7ACFDF4-D852-42FE-95D8-1D2695D5D7BEQ33622982-4E00A30A-E05E-443D-898A-303137AE5269Q33727490-25050189-61E0-42A0-BC31-2D9C02B7D056Q33794923-A9DA8BFB-221C-46C8-9E99-5A0B6C8231FDQ34028551-7122C5DA-99AB-4A84-B4F3-AAD90A595F86Q34139691-6505530E-C6F5-4351-B74A-A25EEB4D77F4Q34382785-479092C0-7467-41C6-A894-B33B5EE212A0Q34436101-EC1DE1D6-FDDA-4E45-B0F5-7104F7BD4F0CQ34457363-C439B8CC-88D0-4069-B100-C9B1AC715D03Q34517849-FE95166F-39FF-42D5-8270-1E9F07D38EA3Q34589774-DD7D589C-255D-4892-AD54-D83A83785C1CQ34766486-C1E28F52-0EA7-4A4C-96AB-3D191E6CE633Q34768930-2E1A4D65-C92D-4943-9C82-D3CFC637CA5CQ34928941-FB152D1C-1739-4105-840E-E57193D05E13Q34991321-0A215898-5E92-4319-A6B1-BC1E5C7E456AQ35059352-395BC968-84C4-4361-8421-CB5858C09570Q35060325-7778E64E-6B9B-4446-A542-960AC9BBA1ADQ35116734-3A13A97F-0754-43FD-B3E2-A4C7777D06B1Q35154233-A64D90CF-191C-4E76-AF41-066358770762Q35673201-D0F1E0F1-691E-49B2-9E76-2A20B5645324Q36158717-B7F93DCA-A9E2-4634-8D3F-3AAAF63685CFQ36185395-D1028635-F222-4920-B5F4-59AE6DC180C0Q36220747-D1DFCF32-48E4-463F-A6FC-50DF6E65EE93Q36259629-829B07E1-433A-4A30-8548-33A460DAD687
P2860
AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
AEE788: a dual family epiderma ...... r and antiangiogenic activity.
@ast
AEE788: a dual family epiderma ...... r and antiangiogenic activity.
@en
AEE788: a dual family epiderma ...... r and antiangiogenic activity.
@nl
type
label
AEE788: a dual family epiderma ...... r and antiangiogenic activity.
@ast
AEE788: a dual family epiderma ...... r and antiangiogenic activity.
@en
AEE788: a dual family epiderma ...... r and antiangiogenic activity.
@nl
prefLabel
AEE788: a dual family epiderma ...... r and antiangiogenic activity.
@ast
AEE788: a dual family epiderma ...... r and antiangiogenic activity.
@en
AEE788: a dual family epiderma ...... r and antiangiogenic activity.
@nl
P2093
P1433
P1476
AEE788: a dual family epiderma ...... r and antiangiogenic activity.
@en
P2093
Careen Tang
Doriano Fabbro
Giorgio Caravatti
Heidi A Lane
Jeanette Wood
Josef Brueggen
Jürgen Mestan
Konstantina Grosios
Markus Wartmann
Paul McSheehy
P304
P356
10.1158/0008-5472.CAN-03-3681
P407
P577
2004-07-01T00:00:00Z